Treatment of Tongue Lymphangioma with Intralesional Combination Injection of Steroid, Bleomycin and Bevacizumab.
10.7181/acfs.2017.18.1.54
- Author:
Jungil HWANG
1
;
Yung Ki LEE
;
Jin Sik BURM
Author Information
1. Department of Plastic Surgery, Kyung Hee University College of Medicine, Seoul, Korea. jsburm@gmail.com
- Publication Type:Case Report
- Keywords:
Lymphangioma;
Tongue;
Steroid;
Bleomycin;
Bevacizumab
- MeSH:
Bevacizumab*;
Bleomycin*;
Child;
Deglutition;
Edema;
Female;
Follow-Up Studies;
Humans;
Lymphangioma*;
Recurrence;
Tongue*;
Triamcinolone;
Vascular Endothelial Growth Factor A
- From:Archives of Craniofacial Surgery
2017;18(1):54-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
Lymphangioma is a congenital malformed lymphatic tumor that rarely involves the tongue. In our clinic, a 10-year-old female presented with lymphangioma circumscriptum involving the right two-thirds of the tongue. We administered an intralesional combination injection of triamcinolone, bleomycin, and bevacizumab as a treatment. Almost complete remission after combination therapy was achieved without complications such as edema, swallowing difficulties or recurrence. Bevacizumab, an inhibitor of vascular endothelial growth factor, was effective for the treatment of lymphangioma of the tongue in this case. No recurrence was noted at the 1-year follow up.
